Check out Pediatrics -- Kramer et al. 108 (2): e39

[Guest guest]

<A

HREF= " http://www.pediatrics.org/cgi/content/full/108/2/e39?maxtoshow= & HITS=10 &

hits=10 & RESULTFORMAT= & searchid=1009931075258_2037 & stored_search= & FIRSTINDEX=0 &

volume=108 & firstpage=E39 & journalcode=pediatrics " >Click here: Pediatrics --

Kramer et al. 108 (2): e39</A>

http://www.pediatrics.org/cgi/content/full/108/2/e39?maxtoshow= & HITS=10 & hits=1

0 & RESULTFORMAT= & searchid=1009931075258_2037 & stored_search= & FIRSTINDEX=0 & volume

=108 & firstpage=E39 & journalcode=pediatrics

The Food and Drug Administration licensed a live-virus varicella vaccine

(Varivax; Merck & Co Inc, West Point, PA) in March 1995. Prelicensure adverse

events were minimal; however, since licensure and increased vaccine use, rare

previously undetected risks have arisen. Presented here is the clinical

course of a previously undiagnosed, human immunodeficiency virus-infected boy

who developed dissemination of the vaccine strain of varicella zoster after

immunization. chickenpox, human immunodeficiency virus, pneumonia,

encephalopathy, varicella vaccine, adverse events, dissemination.